• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.

作者信息

van Rhee Frits, Rossi Jean-François, Simpson David, Fosså Alexander, Dispenzieri Angela, Kuruvilla John, Goh Yeow Tee, Cho Seok-Goo, Capra Marcelo, Liu Ting, Casper Corey, Cavet James, Wong Raymond S

机构信息

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Institut Sainte Catherine, Avignon, France.

出版信息

Br J Haematol. 2021 Jan;192(1):e28-e31. doi: 10.1111/bjh.17177. Epub 2020 Oct 31.

DOI:10.1111/bjh.17177
PMID:33128769
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7820993/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c866/7820993/8965c9889845/BJH-192-e28-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c866/7820993/8965c9889845/BJH-192-e28-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c866/7820993/8965c9889845/BJH-192-e28-g001.jpg

相似文献

1
Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.新诊断和先前接受过治疗的多中心Castleman病对司妥昔单抗的反应相同。
Br J Haematol. 2021 Jan;192(1):e28-e31. doi: 10.1111/bjh.17177. Epub 2020 Oct 31.
2
A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.一项关于司妥昔单抗（一种抗白细胞介素-6单克隆抗体）在多中心Castleman病患者中安全性的2期开放标签多中心研究。
Oncotarget. 2015 Oct 6;6(30):30408-19. doi: 10.18632/oncotarget.4655.
3
Siltuximab for Multicentric Castleman Disease-Letter.关于司妥昔单抗治疗多中心Castleman病的信函。
Clin Cancer Res. 2015 Oct 15;21(20):4740. doi: 10.1158/1078-0432.CCR-15-1310.
4
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.一项评估 siltuximab（一种抗 IL-6 单克隆抗体）在 B 细胞非霍奇金淋巴瘤、多发性骨髓瘤或 Castleman 病患者中的安全性、耐受性、药代动力学和初步疗效的 I 期、开放性研究。
Clin Cancer Res. 2013 Jul 1;19(13):3659-70. doi: 10.1158/1078-0432.CCR-12-3349. Epub 2013 May 9.
5
Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program.西妥昔单抗治疗复发/难治性多中心 Castleman 病：意大利 NPP 项目的经验。
Hematol Oncol. 2018 Oct;36(4):689-692. doi: 10.1002/hon.2532. Epub 2018 Aug 3.
6
Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.西妥昔单抗治疗特发性多中心Castleman病患者的长期安全性：两项试验的预设开放标签扩展分析
Lancet Haematol. 2020 Mar;7(3):e209-e217. doi: 10.1016/S2352-3026(19)30257-1. Epub 2020 Feb 3.
7
Efficacy of siltuximab in the treatment of idiopathic multicentric castleman disease, the first Polish, real-world experience with long-term observation.西妥昔单抗治疗特发性多中心Castleman病的疗效，波兰首例长期观察的真实世界经验。
Leuk Lymphoma. 2021 Dec;62(12):3031-3034. doi: 10.1080/10428194.2021.1941926. Epub 2021 Jun 23.
8
Deriving health utility values from a randomized, double-blind, placebo-controlled trial of siltuximab in subjects with multicentric Castleman's disease.从一项在多中心Castleman病患者中进行的关于西妥昔单抗的随机、双盲、安慰剂对照试验中得出健康效用值。
Curr Med Res Opin. 2016 Jul;32(7):1193-200. doi: 10.1185/03007995.2016.1164675. Epub 2016 Apr 14.
9
Siltuximab for multicentric Castleman disease.司妥昔单抗治疗多中心性Castleman病
Expert Rev Hematol. 2014 Oct;7(5):545-57. doi: 10.1586/17474086.2014.946402. Epub 2014 Aug 9.
10
JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease.与皮肤型Castleman病对司妥昔单抗的特殊反应相关的JAK1基因改变
JAMA Dermatol. 2017 May 1;153(5):449-452. doi: 10.1001/jamadermatol.2016.5554.

引用本文的文献

1
How we manage idiopathic multicentric Castleman disease.我们如何治疗特发性多中心Castleman病。
Clin Adv Hematol Oncol. 2022 Sep;20(9):564-571.

本文引用的文献

1
Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.西妥昔单抗治疗特发性多中心Castleman病患者的长期安全性：两项试验的预设开放标签扩展分析
Lancet Haematol. 2020 Mar;7(3):e209-e217. doi: 10.1016/S2352-3026(19)30257-1. Epub 2020 Feb 3.
2
Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.特发性多中心 Castleman 病的新见解和治疗方法。
Blood. 2018 Nov 29;132(22):2323-2330. doi: 10.1182/blood-2018-05-848671.
3
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
特发性多中心 Castleman 病的国际、循证共识治疗指南。
Blood. 2018 Nov 15;132(20):2115-2124. doi: 10.1182/blood-2018-07-862334. Epub 2018 Sep 4.
4
FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease.FDA 批准：西妥昔单抗治疗多中心型 Castleman 病。
Clin Cancer Res. 2015 Mar 1;21(5):950-4. doi: 10.1158/1078-0432.CCR-14-1678. Epub 2015 Jan 19.
5
Siltuximab for multicentric Castleman disease.司妥昔单抗治疗多中心性Castleman病
Expert Rev Hematol. 2014 Oct;7(5):545-57. doi: 10.1586/17474086.2014.946402. Epub 2014 Aug 9.
6
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.西妥昔单抗治疗多发性 Castleman 病的随机、双盲、安慰剂对照试验。
Lancet Oncol. 2014 Aug;15(9):966-74. doi: 10.1016/S1470-2045(14)70319-5. Epub 2014 Jul 17.
7
HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.HHV-8 阴性、特发性多中心 Castleman 病：生物学、发病机制和治疗的新见解。
Blood. 2014 May 8;123(19):2924-33. doi: 10.1182/blood-2013-12-545087. Epub 2014 Mar 12.
8
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.一项评估 siltuximab（一种抗 IL-6 单克隆抗体）在 B 细胞非霍奇金淋巴瘤、多发性骨髓瘤或 Castleman 病患者中的安全性、耐受性、药代动力学和初步疗效的 I 期、开放性研究。
Clin Cancer Res. 2013 Jul 1;19(13):3659-70. doi: 10.1158/1078-0432.CCR-12-3349. Epub 2013 May 9.
9
The clinical spectrum of Castleman's disease.卡斯特曼病的临床谱。
Am J Hematol. 2012 Nov;87(11):997-1002. doi: 10.1002/ajh.23291. Epub 2012 Jul 13.
10
Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy.21世纪的Castleman病：诊断、评估及治疗的最新进展
Clin Adv Hematol Oncol. 2010 Jul;8(7):486-98.